ESSA Pharma Inc at JMP Securities Life Sciences Conference Transcript

May 16, 2023 / 02:00PM GMT
Unidentified Analyst

Welcome to the second day of the JMP Securities Life Sciences Conference. It's my pleasure to welcome ESSA Pharma, a clinical-stage pharmaceutical company focused on developing therapies for prostate cancer. Here to present for the company is CEO, David Parkinson. David?

David Parkinson - ESSA Pharma Inc. - President, CEO & Director

Brendan, thank you very much. Privileged to be here, and appreciate the invitation. So thank you all for joining. I'd like to, today, describe what we, at ESSA, are doing with respect to our unique approach to early prostate cancer.

ESSA is a company which is focused on a rather unique approach to interfering with the male hormone biology in prostate cancer. I'm here with my colleagues, Peter Virsik, our Chief Operating Officer; and David Wood, our Chief Financial Officer. Not here today is our Chief Medical Officer, who is actually working and developing a drug, if you can believe that.

So what we'll be talking about here briefly today is a unique approach to shutting down androgen-related biology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot